Free Trial
NYSE:ANVS

Annovis Bio Q2 2024 Earnings Report

Annovis Bio logo
$1.61 +0.10 (+6.89%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Annovis Bio EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Annovis Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annovis Bio Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Thursday, August 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Annovis Bio's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Annovis Bio Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Annovis Bio receives noncompliance notification from NYSE
See More Annovis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email.

About Annovis Bio

Annovis Bio (NYSE:ANVS), a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

View Annovis Bio Profile

More Earnings Resources from MarketBeat